Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Public health benefits from legalizing cannabis: both sides of the coin

Ian Mitchell
CMAJ January 05, 2016 188 (1) 63; DOI: https://doi.org/10.1503/cmaj.1150076
Ian Mitchell
Department of Emergency Medicine, University of British Columbia, Kamloops, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Although Spithoff and colleagues mention some benefits of legalizing cannabis, they provide more details about the potential harms. The positives are limited to reducing stigma and “realization of therapeutic benefits.”1

It may be difficult for physicians viewing cannabis through the lens of addiction to see any silver lining from legalization. However, there are both individual and public health benefits that should be balanced against possible harms. The first and most immediate benefit is that patients who use cannabis for therapeutic purposes will no longer fear legal sanctions.

Both the US and Canada are currently dealing with an increase in addiction and death from fentanyl, oxycodone and other opiates. Two large studies have shown about a 25% decrease in deaths from opiate overdose associated with the legalization of medical cannabis and the availability of dispensaries.2,3 The recent COMPASS study found that the use of cannabis for chronic pain has a reasonable safety profile and that patients often used it as a substitute for other more harmful drugs, such as opiates, NSAIDS (nonsteroidal anti-inflammatory drugs) and alcohol.4 Harm reduction experts have also expressed concerns that professional societies are jeopardizing patient health by requiring a much higher standard for the prescribing of cannabis over the prescribing of opioids.5

Legalization of cannabis would remove research blockades to begin proper study of cannabidiol. This compound is not associated with a “high,” is not known to be addictive and has antiseizure, antianxiety and antipsychotic properties.6 Up to this point, proper study of cannabidiol and other cannabinoids has been restricted by their criminalized status.

Letters to the editor

In submitting a letter, you automatically consent to having it appear online/in print. All letters accepted for print will be edited for space and style. See www.cmaj.ca for full versions and competing interests.

Footnotes

  • Go to cmaj.ca for the full-text version of this letter.

References

    1. Spithoff S,
    2. Emerson B,
    3. Spithoff A
    . Cannabis legalization: adhering to public health best practice. CMAJ 2015;187:1211–6.
    1. Powell D,
    2. Pacula RL,
    3. Jacobson M
    . Do medical marijuana laws reduce addictions and deaths related to pain killers? Cambridge, MA: National Bureau of Economic Research; 2015 Jul. Available: www.nber.org/papers/w21345 (accessed 2015 Oct. 15).
    1. Bachhuber MA,
    2. Saloner B,
    3. Cunningham CO,
    4. et al
    . Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med 2014;174:1668–73.
    1. Ware MA,
    2. Wang T,
    3. Shapiro S,
    4. et al.
    COMPASS study team. Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain 2015;16:1233–42.
    1. Lake S,
    2. Kerr T,
    3. Montaner J
    . Prescribing medical cannabis in Canada: Are we being too cautious? Can J Public Health 2015;106:e328–30.
  1. The biology and potential therapeutic effects of cannabidiol. National Institute on Drug Abuse. Available: www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2015/biology-potential-therapeutic-effects-cannabidiol (accessed 2015 Sept. 5).

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire